crystallization communications
Crystallization and preliminary X-ray crystallographic analysis of agkicetin-C from Deinagkistrodon acutus venom
aKey Laboratory of Structural Biology, Chinese Academy of Sciences, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230026, People's Republic of China, bDepartments of Molecular and Cell Biology, School of Life Sciences, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230026, People's Republic of China, cMacCHESS, Cornell High Energy Synchrotron Source, Cornell University, Ithaca, NY 14853, USA, and dBeijing Synchrotron Radiation Facility, Institute of High Energy Physics, Beijing 100039, People's Republic of China
*Correspondence e-mail: lwniu@ustc.edu.cn
The crystallization and preliminary crystallographic analysis of agkicetin-C, a well known platelet glycoprotein Ib (GPIb) antagonist from the venom of Deinagkistrodon acutus found in Anhui Province, China is reported. Crystals of agkicetin-C suitable for were obtained from 1.8 M ammonium sulfate, 40 mM MES pH 6.5 with 2%(v/v) PEG 400. Interestingly, low buffer concentrations of MES seem to be necessary for crystal growth. The crystals of agkicetin-C belong to C2, with unit-cell parameters a = 177.5, b = 97.7, c = 106.8 Å, β = 118.5°, and diffract to 2.4 Å resolution. Solution of the by the molecular-replacement method shows that there are four agkicetin-C molecules in the with a VM value of 3.4 Å3 Da−1, which corresponds to a high solvent content of approximately 64%. Self-rotation function calculations show a single well defined non-crystallographic twofold axis with features that may represent additional elements of non-crystallographic symmetry.
Keywords: snake venoms; C-type lectins; agkicetin-C.
1. Introduction
Cardiovascular disease has been the most common cause of death in the developed world for many years. As currently used anti-thrombotic drugs such as aspirin, clopidogrel and platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor inhibitors (Coller, 1997) do not specifically inhibit shear-induced platelet aggregation, development of new products that could inhibit platelet aggregation by interfering with the GPIb–von Willebrand Factor (VWF) interaction would represent a breakthrough in terms of mechanism of action and could possess potential clinical utility (Wu et al., 2002).
Snake-venom components have received more and more attention in recent years because of their activity in ), including flavocetin-A from Trimeresurus flavoviridis (Taniuchi et al., 1995), alboaggregin-B (AL-B) from T. albolabris (Peng et al., 1991), echicetin from Echis carinatus (Peng et al., 1993), agkicetin from Deinagkistrodon acutus (Chen & Tsai, 1995), jararaca GPIb-binding protein (GPIb-bp) from Bothrops jararaca (Fujimura et al., 1995), tokaracetin from T. tokarensis (Kawasaki et al., 1995), CHH-B from Crotalus horridus horridus (Andrews et al., 1996), mamushigin from Agkistrodon halys blomhoffii (Sakurai et al., 1998) etc. More recently, a traditional platelet glycoprotein VI (GPVI) binding protein, convulxin from C. durissus terrificus, has also been reported to bind to native human GPIbα (Kanaji et al., 2003). These venom proteins exhibit a variety of activities against platelets, suggesting that their exact binding regions and the binding mechanisms to platelet GPIb are not identical. In-depth investigations of their inhibitory mechanisms are expected to contribute to the design of potent GPIb antagonists for therapeutic use. As a result, the crystal structures of these proteins have recently attracted much attention (Fukuda et al., 2000; Murakami et al., 2003; Jasti et al., 2004; Huang et al., 2004).
processes. GPIb-binding proteins have been purified from snake venoms of many different genera (Andrews & Berndt, 2000Here, we report the crystallization and preliminary crystallographic analysis of agkicetin-C from the venom of D. acutus, a snake from the Anhui Province of China. Like many of these venom components, agkicetin-C is a heterodimer. Agkicetin-C strongly inhibits platelet aggregation induced by ristocetin (Chen & Tsai, 1995), botrocetin or low concentrations of α-thrombin and also completely blocks the adhesion of platelets to human type III collagen under high stress without causing thrombocytopenia in vitro (to be published elsewhere), all of which strongly suggest the potential value of this unique component for clinical utility.
2. Materials and methods
2.1. Purification, N-terminal sequencing and mass-spectrometric peptide analysis of agkicetin-C
1 g of crude D. acutus venom (purchased from Huangshan Institute of Snakes, Anhui, China) was first fractioned by on DEAE-Sepharose (Amersham-Pharmacia, Uppsala, Sweden) and agkicetin-C was then purified by a minor modification of Chen's method (Chen & Tsai, 1995) (Fig. 1). Fractions containing agkicetin-C were identified in a ristocetin-dependent aggregation assay.
The purity of this agkicetin-C preparation was verified by SDS–PAGE followed by Coomassie Brilliant Blue R-250 staining of the protein bands; native polyacrylamide gel S-pyridylethylated according to the method of Atoda et al. (1991) (Fig. 2) and N-terminal sequencing was performed with a Procise 491 protein sequencer (Applied Biosystems, USA).
was also performed to test the under non-denaturing conditions. Purified agkicetin-C was then reduced andFor further analysis, protein bands in the SDS–PAGE were excized from the gel and washed with 50 mM (NH4)2CO3/acetonitrile three times. Proteins were reduced, acetylated and digested with trypsin in the gel. After gel extraction, all were collected for mass-spectrometric peptide analysis on a Biflex III MALDI–TOF (Bruker Daltonik GmbH, Bremen, Germany) (Table 1).
|
2.2. Crystallization
Lyophilized agkicetin-C dissolved in distilled water was screened by typical hanging-drop vapour-diffusion methods with Crystal Screens I and II (Hampton Research, USA). Briefly, 2.0 µl protein solution (30 mg ml−1) was mixed with 2.0 µl of the screening agent and equilibrated against 400 µl reservoir solution at room temperature. Crystals of agkicetin-C appeared after one week under condition No. 38 (1.4 M sodium citrate, 0.1 M Na HEPES pH 7.5) of Crystal Screen I. Unfortunately, these good-looking crystals failed to respond to optimization trials and could not be used for data collection. Only after nearly a year was a small trapezoid-shaped crystal of agkicetin-C found under condition No. 39 (2% PEG 400, 0.1 M Na HEPES pH 7.5, 2.0 M ammonium sulfate) of Crystal Screen I. After carefully searching using various pH values, additives, ions, reservoir solution concentrations etc., we ultimately discovered the optimum condition for crystal growth by the accidental use of a lower buffer concentration. On comparing the crystals grown using different buffer concentrations, we found that different MES concentrations strongly affected crystal growth (data not shown). The best crystals of agkicetin-C (0.3 × 0.3 × 0.08 mm; Fig. 3) were finally obtained using 40 mg ml−1 protein mixed with 1.8 M ammonium sulfate, 2% PEG 400, 40 mM MES pH 6.5 at 293 K after three weeks.
2.3. Collection and reduction of X-ray diffraction data
Diffraction data were collected from crystals of agkicetin-C at beamline 3wla, Beijing Synchrotron Radiation Facility, Institute of High Energy Physics, China (λ = 1.1 Å). Agkicetin-C crystals were mounted in loops after a soaking step in the crystallization solution augmented with 25%(v/v) glycerol as a cryoprotectant. The crystal used in data collection was flash-frozen in a stream of liquid nitrogen at 100 K. Data sets were collected on a MAR CCD detector with a 120 mm crystal-to-detector distance in 1.0° oscillation steps over a range of 140°. Diffraction data were processed with the autoMAR program v.1.4.2 (Bartels & Klein, 2003). The statistics of data collection and reduction are listed in Table 2.
‡Rmerge = , where I(h)j is the jth observed reflection intensity and 〈I(h)〉 is the mean intensity of reflection h. |
3. Results
3.1. Purification and determination of agkicetin-C
Agkicetin-C was purified from the venom of D. acutus from Anhui Province, China. As a sequence has been reported from the same origin (GenBank accession No. AY091762) that is identical to the α subunit of agkicetin-C except for two substitutions at residues 8 (Ser/Cys) and 46 (Arg/Gly), possible evidence of we further investigated our component. The results of N-terminal sequencing gave DCLPGWSSY for the α subunit and DCPPDWSSY for the β subunit, respectively, which proves that the amino acid at position 8 of our protein is Ser. For the other substitution site, we turned to the results of the mass-spectrometric peptide analysis. The molecular weights of the peptide fragments match those calculated from the cDNA sequences well (Chen et al., 2000), but position 46 is at a break between fragments, indicating that there is in fact a trypsin-cleavage site after position 46. The molecular weights of the on either side of the cleavage site closely match the values calculated from the cDNA sequence of agkicetin-C, so that the weight of the evidence is consistent with the amino acid at position 46 of our protein being Arg.
3.2. Preliminary X-ray crystallographic analysis and refinement
The crystals of agkicetin-C belonged to the monoclinic C2 and diffracted to 2.4 Å resolution. Molecular-replacement analysis showed that four agkicetin-C molecules were located in the the VM value was 3.4 Å3 Da−1, which is within the expected range (Matthews, 1968). This VM value corresponds to a solvent content of approximately 64%.
The molecular-replacement analysis was performed with the program AMoRe (Navaza, 1994). After eliminating all water molecules, one αβ heterodimer of the structure of flavocetin-A (PDB code 1c3a ) was chosen as the search model (57 and 66% identity between the α and β subunits of the two proteins, respectively). The rotation search was performed with a radius of 30 Å and an angular step size of 2.5° within the resolution range 15.0–3.0 Å. The (44.7%) and R factor (47.3%) of the initial solution for four agkicetin-C molecules in an are reasonable and values for the next best solutions were far from these. One obvious self-rotation peak at about a third of the height of the proper crystallographic axes was identified in the suggesting a possible non-crystallographic twofold axis in the Results of initial model building with the program O (Jones et al., 1991) and with the program package CNS v.1.1 (Brünger et al., 1998) confirm a correct solution and intensive crystallographic of the model is under way.
4. Discussion
Agkicetin-C was first reported to have been isolated from D. acutus by Chen & Tsai (1995). It was also found to bind to the platelet glycoprotein Ib–IX–V (GPIb-IX-V) complex and to inhibit VWF-induced platelet agglutination when bound. Later, the complete amino-acid sequence was resolved by cDNA cloning and a putative three-dimensional model was constructed based on the of the homologous habu factor IX/X-binding protein (Chen et al., 2000), which was the first three-dimensional structural model of a snake-venom GPIb-binding protein to our knowledge.
Determination of the e.g. flavocetin-A and echicetin) or target more than one platelet receptor (e.g. convulxin), it is hoped that the of agkicetin-C will provide new details of GPIb binding by these snake-venom proteins.
of agkicetin-C was has been prevented until now because of difficulties in its crystallization. In this communication, we report the crystallization of agkicetin-C. This is the first crystallization of a snake-venom GPIb-binding protein that only has an inhibitory effect on platelet aggregation to be reported. When compared with the structures of other snake-venom GPIb-binding protein, which can either inhibit or induce platelet aggregation (Acknowledgements
Financial support for this project to LN and MT was provided by research grants from the Chinese National Natural Science Foundation (grant Nos. 30121001, 30025012 and 30130080), the `973' and `863' Plans of the Chinese Ministry of Science and Technology (grant Nos. G1999075603 and 2002BA711A13) and the Chinese Academy of Sciences (grant No. KSCX1-SW-17).
References
Andrews, R. K. & Berndt, M. C. (2000). Toxicon, 38, 775–791. Web of Science CrossRef PubMed CAS Google Scholar
Andrews, R. K., Kroll, M. H., Ward, C. M., Rose, J. W., Scarborough, R. M., Smith, A. I., Lopez, J. A. & Berndt, M. C. (1996). Biochemistry, 35, 12629–12639. CrossRef CAS PubMed Web of Science Google Scholar
Atoda, H., Hyuga, M. & Morita, T. (1991). J. Biol. Chem. 266, 14903–14911. PubMed CAS Web of Science Google Scholar
Bartels K. S. & Klein C. (2003). The automar Manual, version 1.4. Norderstedt, Germany: marresearch GmbH. Google Scholar
Brünger, A. T., Adams, P. D., Clore, G. M., Delano, W. L., Gros, P., Grosse-Kunstleve, R. W., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. & Warren, G. L. (1998). Acta Cryst. D54, 905–921. Web of Science CrossRef IUCr Journals Google Scholar
Chen, Y. L. & Tsai, I. H. (1995). Biochem. Biophys. Res. Commun. 210, 472–477. CrossRef CAS PubMed Web of Science Google Scholar
Chen, Y. L., Tsai, K. W., Chang, T., Hong, T. M. & Tsai, I. H. (2000). Thromb. Haemost. 83, 119–126. Web of Science PubMed CAS Google Scholar
Coller, B. S. (1997). J. Clin. Invest. 100, S57–S60. Web of Science CAS PubMed Google Scholar
Fujimura, Y., Ikeda, Y., Miura, S., Yoshida, E., Shima, H., Nishida, S., Suzuki, M., Titani, K., Taniuchi, Y. & Kawasaki, T. (1995). Thromb. Haemost. 74, 743–750. CAS PubMed Web of Science Google Scholar
Fukuda, K., Mizuno, H., Atoda, H. & Morita, T. (2000). Biochemistry, 39, 1915–1923. Web of Science CrossRef PubMed CAS Google Scholar
Huang, K. F., Ko, T.-P., Hung, C. C., Chu, J., Wang, A. H. & Chiou, S. H. (2004). Biochem J. 378, 399–407. Web of Science CrossRef PubMed CAS Google Scholar
Jasti, J., Paramasivam, M., Srinivasan, A. & Singh, T. P. (2004). J. Mol. Biol. 335, 167–176. Web of Science CrossRef PubMed CAS Google Scholar
Jones, T. A., Zou, J. Y., Cowan, S. W. & Kjeldgaard, M. (1991). Acta Cryst. A47, 110–119. CrossRef CAS Web of Science IUCr Journals Google Scholar
Kanaji, S., Kanaji, T., Furihata, K., Kato, K., Ware, L. J. & Kunicki, T. J. (2003). J. Biol. Chem. 278, 39452–39460. Web of Science CrossRef PubMed CAS Google Scholar
Kawasaki, T., Taniuchi, Y., Hisamichi, N., Fujimura, Y., Suzuki, M., Titani, K, Sakai, Y., Kaku, S., Satoh, N., Takenaka, T., Handa, M. & Sawai, Y. (1995). Biochem. J. 308, 947–953. CAS PubMed Web of Science Google Scholar
Matthews, B. W. (1968). J. Mol. Biol. 33, 491–497. CrossRef CAS PubMed Web of Science Google Scholar
Murakami, M. T., Zela, S. P., Gava, L. M., Michelan-Duarte, S., Cintra, A. C. O. & Arnia, R. K. (2003). Biochem. Biophys. Res. Commun. 310, 478–482. Web of Science CrossRef PubMed CAS Google Scholar
Navaza, J. (1994). Acta Cryst. A50, 157–163. CrossRef CAS Web of Science IUCr Journals Google Scholar
Peng, M., Lu, W., Beviglia, L., Niewiarowski, S. & Kirby, E. P. (1993). Blood, 81, 2321–2328. CAS PubMed Web of Science Google Scholar
Peng, M., Lu, W. & Kirby, E. P. (1991). Biochemistry, 30, 11529–11536. CrossRef PubMed CAS Web of Science Google Scholar
Sakurai, Y., Fujimura, Y., Kokubo T., Imamura, K., Kawasaki, T., Handa, M., Suzuki, M., Matsui, T., Titani, K. & Yoshioka, A. (1998). Thromb. Haemost. 79, 1199–1207. Google Scholar
Taniuchi, Y., Kawasaki, T., Fujimura, Y., Suzuki, M., Titani, K., Sakai, Y., Kaku, S., Hisamichi, N., Satoh, N., Takenaka, T., Handa, M. & Sawai, Y. (1995). Biochim. Biophys. Acta, 1244, 331–338. CrossRef CAS PubMed Web of Science Google Scholar
Wu, D., Meiring, M., Kotze, H. F., Deckmyn, H. & Cauwenberghs, N. (2002). Arterioscler. Thromb. Vasc. Biol. 22, 323–328. Web of Science CrossRef PubMed CAS Google Scholar
© International Union of Crystallography. Prior permission is not required to reproduce short quotations, tables and figures from this article, provided the original authors and source are cited. For more information, click here.